SSG&PM SP: Nuevo tratamiento contra el kala-azar, la enfermedad parasitaria más mortal después de la malaria. Se necesita apoyo urgente que permita a los gobiernos poner en marcha el tratamiento y controlar la enfermedad

[Nairobi, 23 de septiembre de 2011]

África oriental lucha en estos momentos contra el peor brote de kala-azar de la última década. Gracias a una colaboración llevada a cabo en toda la región a través de la Plataforma para la Leishmaniasis en el Este de África (LEAP, por sus siglas en inglés) se ha desarrollado una nueva combinación terapéutica (EGS + PM) más barata y que disminuye casi a la mitad el ciclo de tratamiento – de 30 días de inyecciones a 17 días- . Los países del África oriental están tomando las medidas regulatorias necesarias para usar este tratamiento dentro de sus programas, pero los expertos alertan de que pocos pacientes se beneficiarán sin los fondos internacionales necesarios y el interés y el apoyo a los gobiernos para su puesta en marcha.

Progress in India in Medical Research New Treatments for Neglected Diseases from Research to Implementation

[New Delhi, India – December 3, 2010]
Over 150 Indian and international health researchers, policy makers, experts from 22 countries met on December 3rd, at the Constitutional Club in New Delhi for the 3rd International Partners meeting organized by Drugs for Neglected Diseases initiative (DNDi) in collaboration with Indian Council for Medical Research (ICMR) to stimulate greater regional research partnership to fight the most neglected diseases such as Kala-azar sleeping sickness, malaria and Chagas disease.

Dutch Government gives 14 million Euros to DNDi to fight neglected tropical diseases

[Geneva, Switzerland – December 3, 2010]
The Ministry of Foreign Affairs of the Netherlands has granted 14 million Euros to the Drugs for Neglected Diseases initiative (DNDi) to fight neglected tropical diseases. The grant will be disbursed over four years (2011-2014) and will provide critical funding for DNDi on the core disease programmes for human African trypanosomiasis, Chagas disease, and leishmaniasis. This is the second time that the Dutch government has awarded funding to DNDi.

ASTMH 2010

[November 3-7, 2010]
Atlanta, USA
The Drugs for Neglected Diseases initiative (DNDi) will participate in several activities at ASTMH 2010, including a joint symposium with Central Drug Research Institute (CDRI) on Visheral Leishmaniasis (VL) in the Indian Continent, a second symposium on VL in East Africa, a satellite symposium on Challenges and Successes of the FACT Project through Innovative Partnerships for the development of Artesunate Combination Therapies for Malaria, as well as several oral presentations.

Geographical variation in the response of visceral leishmaniasis to Paromomycin in East Africa: A multicentre, open-label, randomized trial

by Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Muellerm, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J, for the Leishmaniasis East Africa Platform (LEAP) group.

PLoS Negl Trop Dis, October 2010

New Potential TB Drugs to be Investigated Against Multiple Neglected Diseases

[New York, United States and Geneva, Switzerland – July 7, 2010]
A Unique Collaboration: TB Alliance and DNDi Enter Cross-Disease License Agreement to Speed Development of Novel Therapies
The Global Alliance for TB Drug Development (TB Alliance) and Drugs for Neglected Diseases initiative (DNDi) announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world’s poor. This agreement highlights the efficiency and synergy of product development partnerships (PDPs), and how investment in PDPs is producing a robust and diverse pipeline of tools to treat a wide variety of neglected diseases.

More Sustainable Resources Needed

[February 2010]
Despite the establishment of Product Development Partnerships like DNDi and new commitments from public and private donors, funding for scientific and medical innovation for diseases that disproportionately affect the developing world remains inadequate. DNDi and the George Institute launched in February 2010 a new report on the challenges of registering new drugs for neglected diseases in the African context.

Pfizer and DNDi Advancing International Research Efforts in The Fight Against Neglected Tropical Diseases

[New York, USA, Geneva, Switzerland – November 18, 2009]
Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.